EWTX
Edgewise Therapeutics, Inc.$43.61-1.03 (-2.32%)Prev Close$44.62·MCap$4.63B·P/E—·Vol1.39M·Yield—
▲
Buys (12M)
1
$199.4K
▼
Sells (12M)
12
$19.50M
◆
Net Activity
Net Seller
$19.30M
●
Active Insiders
7
last 12 mo
Over the past 12 months, insider activity at Edgewise Therapeutics, Inc. (EWTX) has been dominated by selling, with 1 insider purchase totaling $199.4K and 12 insider sales totaling $19.50M. The most recent insider transaction was by Donovan Joanne M. (officer: CMO), who sold $412.7K worth of shares on Aug 14, 2026. Edgewise Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $4.63B.
EWTX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Donovan Joanne M. | officer: CMO | Sell | 9,441 | $43.71 | $412.7K | 15,227-38% |
| Aug 14, 2026 | MOORE JOHN R | officer: General Counsel | Sell | 5,016 | $43.82 | $219.8K | 20,274 |
| Aug 14, 2026 | Derakhshan Behrad | officer: Chief Business Officer | Sell | 5,100 | $43.81 | $223.4K | 34,755 |
| Aug 14, 2026 | Russell Alan J | director, officer: Chief Scientific Officer | Sell | 5,901 | $43.73 | $258.0K | 34,129 |
| Aug 14, 2026 | KOCH KEVIN | director, officer: President and CEO | Sell | 17,971 | $43.68 | $785.0K | 61,677 |
| Jul 2, 2026 | Russell Alan J | director, officer: Chief Scientific Officer | Sell | 200,000 | $39.41 | $7.88M | 94,203-68% |
| May 5, 2026 | Donovan Joanne M. | officer: CMO | Sell | 55,230 | $37.88 | $2.09M | 4,367-93% |
| Apr 2, 2026 | Donovan Joanne M. | officer: CMO | Sell | 28,662 | $32.31 | $926.1K | 9,597-75% |
| Mar 31, 2026 | Donovan Joanne M. | officer: CMO | Sell | 21,338 | $32.12 | $685.3K | 9,597-69% |
| Mar 30, 2026 | Donovan Joanne M. | officer: CMO | Sell | 16,358 | $30.98 | $506.7K | 16,332-50% |
| Jan 21, 2026 | Edris Badreddin | Director | Sell | 115,471 | $29.44 | $3.40M | 0 |
| Nov 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $21.12 | $2.11M | 0 |
| Nov 11, 2025 | Fox Jonathan C | Director | Buy | 10,700 | $18.64 | $199.4K | 0 |
| Aug 26, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $14.60 | $1.46M | 0 |
| Aug 12, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,428 | $13.39 | $19.1K | 0 |
| Aug 12, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 2,491 | $13.39 | $33.4K | 0 |
| Aug 12, 2025 | Donovan Joanne M. | CMO | Sell | 2,862 | $13.39 | $38.3K | 0 |
| Aug 12, 2025 | KOCH KEVIN | President and CEO | Sell | 7,972 | $13.39 | $106.8K | 0 |
| Aug 12, 2025 | MOORE JOHN R | General Counsel | Sell | 2,098 | $13.39 | $28.1K | 0 |
| Aug 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,907 | $13.39 | $25.5K | 0 |
| May 1, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,314 | $16.45 | $21.6K | 0 |
| May 1, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 1,691 | $16.45 | $27.8K | 0 |
| May 1, 2025 | Donovan Joanne M. | CMO | Sell | 5,187 | $16.45 | $85.3K | 0 |
| May 1, 2025 | KOCH KEVIN | President and CEO | Sell | 4,276 | $16.45 | $70.4K | 0 |
| May 1, 2025 | MOORE JOHN R | General Counsel | Sell | 1,930 | $16.45 | $31.8K | 0 |
| May 1, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,551 | $16.45 | $25.5K | 0 |
| Apr 3, 2025 | Thompson Peter A. | Director | Buy | 496,771 | $20.13 | $10.00M | 0 |
| Mar 7, 2025 | KOCH KEVIN | President and CEO | Sell | 100 | $30.00 | $3.0K | 0 |
| Mar 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 200 | $30.02 | $6.0K | 0 |
| Feb 7, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $30.03 | $300.3K | 16,837-37% |
| Feb 7, 2025 | KOCH KEVIN | President and CEO | Sell | 9,536 | $30.13 | $287.3K | 14,478-40% |
| Feb 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 9,215 | $30.04 | $276.8K | 14,863-38% |
| Jan 30, 2025 | Donovan Joanne M. | CMO | Sell | 25,000 | $27.63 | $690.7K | 16,358-60% |
| Dec 31, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $27.37 | $2.74M | 14,863-87% |
| Dec 27, 2024 | Semigran Marc | Chief Development Officer | Sell | 29,709 | $29.69 | $881.9K | 8,445-78% |
| Sep 24, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 125,092 | $28.57 | $3.57M | 35,928-78% |
| Sep 24, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 42,068 | $29.03 | $1.22M | 15,121-74% |
| Sep 24, 2024 | Donovan Joanne M. | CMO | Sell | 7,162 | $28.29 | $202.6K | 14,538-33% |
| Sep 24, 2024 | MOORE JOHN R | General Counsel | Sell | 70,922 | $28.15 | $2.00M | 3,252-96% |
| Sep 24, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 75,000 | $28.27 | $2.12M | 13,534-85% |
| May 3, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 2,157 | $18.91 | $40.8K | 35,230 |
| May 3, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 1,718 | $18.91 | $32.5K | 13,422 |
| May 3, 2024 | Donovan Joanne M. | CMO | Sell | 3,682 | $18.91 | $69.6K | 19,897 |
| May 3, 2024 | KOCH KEVIN | President and CEO | Sell | 3,152 | $18.91 | $59.6K | 14,478 |
| May 3, 2024 | MOORE JOHN R | General Counsel | Sell | 1,956 | $18.91 | $37.0K | 3,252-38% |
| May 3, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 1,576 | $18.91 | $29.8K | 7,238 |
| Feb 9, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $20.03 | $200.3K | 7,020-59% |
| Feb 9, 2024 | MOORE JOHN R | General Counsel | Sell | 29,835 | $20.00 | $596.8K | 0Exit |
| Jan 25, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 90,000 | $15.78 | $1.42M | 29,024-76% |
| Jan 25, 2024 | Thompson Peter A. | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,497 |
Showing 1–50 of 85
1 / 2
EWTX Insider Buying Activity
The following table shows recent insider purchases of Edgewise Therapeutics, Inc. (EWTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 11, 2025 | Fox Jonathan C | Director | Buy | 10,700 | $18.64 | $199.4K | 0 |
| Apr 3, 2025 | Thompson Peter A. | Director | Buy | 496,771 | $20.13 | $10.00M | 0 |
| Jan 25, 2024 | Thompson Peter A. | Director | Buy | 454,545 | $11.00 | $5.00M | 14,436,497 |
EWTX Insider Selling Activity
The following table shows recent insider sales of Edgewise Therapeutics, Inc. (EWTX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Aug 14, 2026 | Donovan Joanne M. | officer: CMO | Sell | 9,441 | $43.71 | $412.7K | 15,227-38% |
| Aug 14, 2026 | MOORE JOHN R | officer: General Counsel | Sell | 5,016 | $43.82 | $219.8K | 20,274 |
| Aug 14, 2026 | Derakhshan Behrad | officer: Chief Business Officer | Sell | 5,100 | $43.81 | $223.4K | 34,755 |
| Aug 14, 2026 | Russell Alan J | director, officer: Chief Scientific Officer | Sell | 5,901 | $43.73 | $258.0K | 34,129 |
| Aug 14, 2026 | KOCH KEVIN | director, officer: President and CEO | Sell | 17,971 | $43.68 | $785.0K | 61,677 |
| Jul 2, 2026 | Russell Alan J | director, officer: Chief Scientific Officer | Sell | 200,000 | $39.41 | $7.88M | 94,203-68% |
| May 5, 2026 | Donovan Joanne M. | officer: CMO | Sell | 55,230 | $37.88 | $2.09M | 4,367-93% |
| Apr 2, 2026 | Donovan Joanne M. | officer: CMO | Sell | 28,662 | $32.31 | $926.1K | 9,597-75% |
| Mar 31, 2026 | Donovan Joanne M. | officer: CMO | Sell | 21,338 | $32.12 | $685.3K | 9,597-69% |
| Mar 30, 2026 | Donovan Joanne M. | officer: CMO | Sell | 16,358 | $30.98 | $506.7K | 16,332-50% |
| Jan 21, 2026 | Edris Badreddin | Director | Sell | 115,471 | $29.44 | $3.40M | 0 |
| Nov 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $21.12 | $2.11M | 0 |
| Aug 26, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $14.60 | $1.46M | 0 |
| Aug 12, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,428 | $13.39 | $19.1K | 0 |
| Aug 12, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 2,491 | $13.39 | $33.4K | 0 |
| Aug 12, 2025 | Donovan Joanne M. | CMO | Sell | 2,862 | $13.39 | $38.3K | 0 |
| Aug 12, 2025 | KOCH KEVIN | President and CEO | Sell | 7,972 | $13.39 | $106.8K | 0 |
| Aug 12, 2025 | MOORE JOHN R | General Counsel | Sell | 2,098 | $13.39 | $28.1K | 0 |
| Aug 12, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,907 | $13.39 | $25.5K | 0 |
| May 1, 2025 | Carruthers R Michael | Chief Financial Officer | Sell | 1,314 | $16.45 | $21.6K | 0 |
| May 1, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 1,691 | $16.45 | $27.8K | 0 |
| May 1, 2025 | Donovan Joanne M. | CMO | Sell | 5,187 | $16.45 | $85.3K | 0 |
| May 1, 2025 | KOCH KEVIN | President and CEO | Sell | 4,276 | $16.45 | $70.4K | 0 |
| May 1, 2025 | MOORE JOHN R | General Counsel | Sell | 1,930 | $16.45 | $31.8K | 0 |
| May 1, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 1,551 | $16.45 | $25.5K | 0 |
| Mar 7, 2025 | KOCH KEVIN | President and CEO | Sell | 100 | $30.00 | $3.0K | 0 |
| Mar 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 200 | $30.02 | $6.0K | 0 |
| Feb 7, 2025 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $30.03 | $300.3K | 16,837-37% |
| Feb 7, 2025 | KOCH KEVIN | President and CEO | Sell | 9,536 | $30.13 | $287.3K | 14,478-40% |
| Feb 7, 2025 | Russell Alan J | Chief Scientific Officer | Sell | 9,215 | $30.04 | $276.8K | 14,863-38% |
| Jan 30, 2025 | Donovan Joanne M. | CMO | Sell | 25,000 | $27.63 | $690.7K | 16,358-60% |
| Dec 31, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 100,000 | $27.37 | $2.74M | 14,863-87% |
| Dec 27, 2024 | Semigran Marc | Chief Development Officer | Sell | 29,709 | $29.69 | $881.9K | 8,445-78% |
| Sep 24, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 125,092 | $28.57 | $3.57M | 35,928-78% |
| Sep 24, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 42,068 | $29.03 | $1.22M | 15,121-74% |
| Sep 24, 2024 | Donovan Joanne M. | CMO | Sell | 7,162 | $28.29 | $202.6K | 14,538-33% |
| Sep 24, 2024 | MOORE JOHN R | General Counsel | Sell | 70,922 | $28.15 | $2.00M | 3,252-96% |
| Sep 24, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 75,000 | $28.27 | $2.12M | 13,534-85% |
| May 3, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 2,157 | $18.91 | $40.8K | 35,230 |
| May 3, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 1,718 | $18.91 | $32.5K | 13,422 |
| May 3, 2024 | Donovan Joanne M. | CMO | Sell | 3,682 | $18.91 | $69.6K | 19,897 |
| May 3, 2024 | KOCH KEVIN | President and CEO | Sell | 3,152 | $18.91 | $59.6K | 14,478 |
| May 3, 2024 | MOORE JOHN R | General Counsel | Sell | 1,956 | $18.91 | $37.0K | 3,252-38% |
| May 3, 2024 | Russell Alan J | Chief Scientific Officer | Sell | 1,576 | $18.91 | $29.8K | 7,238 |
| Feb 9, 2024 | Derakhshan Behrad | Chief Business Officer | Sell | 10,000 | $20.03 | $200.3K | 7,020-59% |
| Feb 9, 2024 | MOORE JOHN R | General Counsel | Sell | 29,835 | $20.00 | $596.8K | 0Exit |
| Jan 25, 2024 | Carruthers R Michael | Chief Financial Officer | Sell | 90,000 | $15.78 | $1.42M | 29,024-76% |
EWTX Insiders
Similar Stocks to EWTX
VRTX
Vertex Pharmaceuticals Incorporated
$513.52-1.17%
$132.26B
REGN
Regeneron Pharmaceuticals, Inc.
$772.87-2.63%
$83.21B
MRNA
Moderna, Inc.
$142.93-2.49%
$57.13B
RVMD
Revolution Medicines, Inc.
$204.47-0.31%
$44.15B
INSM
Insmed Incorporated
$119.56-4.63%
$28.05B
INCY
Incyte Corporation
$121.65-0.43%
$24.62B
UTHR
United Therapeutics Corporation
$500.44-0.42%
$21.10B
NBIX
Neurocrine Biosciences, Inc.
$150.44-4.31%
$15.71B